625. SPR206 Pharmacokinetics (PK) in Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) in Healthy Adult Subjects

BACKGROUND: SPR206 is a novel intravenously (IV)-administered next-generation polymyxin being developed for the treatment of multi-drug resistant (MDR) Gram-negative (GN) infections. A Phase 1 bronchoalveolar lavage (BAL) study was conducted to evaluate SPR206 safety and PK in plasma and pulmonary m...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodvold, Keith A, Bader, Justin, Gupta, Vipul K, Lister, Troy, Srivastava, Praveen, Bruss, Jon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752302/
http://dx.doi.org/10.1093/ofid/ofac492.677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752302/
http://dx.doi.org/10.1093/ofid/ofac492.677

Ejemplares similares